Amgen Other Non-Current Liabilities 2010-2025 | AMGN

Amgen other non-current liabilities for the quarter ending June 30, 2025 were $4.847B, a 6.11% increase year-over-year.

  • Amgen other non-current liabilities for 2024 were $4.698B, a 32.94% decline from 2023.
  • Amgen other non-current liabilities for 2023 were $7.006B, a 16.67% decline from 2022.
  • Amgen other non-current liabilities for 2022 were $8.408B, a 7.19% decline from 2021.

Amgen Other Non-Current Liabilities 2010-2025 | AMGN

  • Amgen other non-current liabilities for 2024 were $4.698B, a 32.94% decline from 2023.
  • Amgen other non-current liabilities for 2023 were $7.006B, a 16.67% decline from 2022.
  • Amgen other non-current liabilities for 2022 were $8.408B, a 7.19% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$248.1B
Gilead Sciences (GILD)$139.7B
Vertex Pharmaceuticals (VRTX)$100.5B
Bristol Myers Squibb (BMY)$95.4B
GSK (GSK)$80.3B
CSL (CSLLY)$66.8B
Regeneron Pharmaceuticals (REGN)$61.4B
Alnylam Pharmaceuticals (ALNY)$59.3B
Argenex SE (ARGX)$43.1B
Insmed (INSM)$28.5B
BioNTech SE (BNTX)$24.5B
Royalty Pharma (RPRX)$20.8B
Biogen (BIIB)$19.4B
Genmab (GNMSF)$16.4B
Incyte (INCY)$16.3B
Genmab (GMAB)$16.1B
Illumina (ILMN)$15.2B
Ascendis Pharma (ASND)$11.9B
BioMarin Pharmaceutical (BMRN)$11.1B
Swedish Orphan Biovitrum (BIOVF)$10.9B
QIAGEN (QGEN)$10.3B
Exelixis (EXEL)$10.2B
Moderna (MRNA)$9.5B
Verona Pharma American Depositary Share (VRNA)$9.2B
Exact Sciences (EXAS)$8.9B
Bio-Techne Corp (TECH)$8.5B
Halozyme Therapeutics (HALO)$8.5B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.2B
Guardant Health (GH)$8B